Nav: Home

ESC Congress Hot Lines target heart failure, prevention and coronary artery disease

July 27, 2016

Sophia Antipolis, 27 July 2016: The highly anticipated ESC Congress 2016 hot lines are set to reveal the latest discoveries in the fields of heart failure, cardiovascular disease (CVD) prevention, and coronary artery disease in six packed sessions.

Six Hot Lines sessions:

Innovative approaches for the treatment of heart failure (HF) will be presented in five trials:
  • DANISH: Effect of implantable cardioverter defibrillator on mortality in non-ischaemic systolic HF

  • REM-HF: Evaluation of implantable devices using remote monitoring

  • MORE-CARE: Impact of remotely monitoring biventricular defibrillators on outcomes and resources

  • CHART-1: Cardiopoietic regenerative therapy for congestive HF

  • Allogeneic mesenchymal stem cells for non-ischaemic cardiomyopathy
Preventive strategies will be unveiled in acute coronary syndromes (ACS), sleep apnoea, and hypertension:
  • NIPPON: Optimal dual antiplatelet treatment duration following bioabsorbable drug eluting stent

  • ANTARCTIC: Platelet function monitoring in elderly patients stented for ACS

  • SAVE: Results from the sleep apnoea cardiovascular endpoints study

  • NACIAM: Early N-acetylcysteine with glyceryl trinitrate in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

  • Median nerve modulation: A novel approach to resistant hypertension
Novel preventive treatments in lipids will be released:
  • HIJ-PROPER: LDL cholesterol targeting with pitavastatin plus ezetimibe

  • OPTICARE: Trial of educational and behavioural intervention for cardiac rehabilitation

  • Effect of long-term lower LDL cholesterol, lower systolic blood pressure, or both on risk of CVD

  • ESCAPE: Effect of alirocumab on frequency of lipoprotein apheresis

  • Apheresis as a novel treatment for refractory angina with raised lipoprotein(a)

The use of imaging in the diagnosis and management of coronary artery disease will be discussed:
  • CONSERVE: Direct versus selective catheterisation guided by coronary computed tomography (CT) in stable coronary artery disease

  • DOCTORS: Does Optical Coherence Tomography Optimise Results of Stenting?

  • CE-MARC 2: Diagnostic strategies in patients with suspected coronary heart disease

  • PACIFIC trial: Head-to-head comparison of coronary CT angiography, myocardial perfusion SPECT, PET, and hybrid imaging for diagnosis of ischaemic heart disease

  • AMERICA: Multivascular versus coronary disease treatment alone
Coronary artery disease and stenting is the focus of a dedicated session:
  • NorStent: Long term effects of new generation drug eluting versus contemporary bare metal stents

  • BASKET-SAVAGE: Drug eluting versus bare metal stents in saphenous vein grafts

  • PRAGUE -18: Ticagrelor versus prasugrel in ST-segment elevation myocardial infarction

  • Antithrombotic therapy without stenting for patients with ACS caused by plaque erosion

  • BBK II: Culotte versus T-stenting for treatment of coronary bifurcation lesions

New preventive strategies:
  • ENSURE-AF: Edoxaban for cardioversion of atrial fibrillation

  • ANNEXA-4: Andexanet alfa to reverse Factor Xa inhibitors in acute major bleeding

  • REVERSE II: Identifying venous thromboembolism patients who can discontinue anticoagulants

  • SENTINEL: Cerebral protection in transcatheter aortic valve replacement

  • YEARS: Simplified diagnostic management algorithm for acute pulmonary embolism

Additional late breaking science will be presented with 25 clinical trial updates, 24 registries and 12 basic and translational hot lines presentations.

Original science will also be showcased in the different abstract sessions - the Advances in Science, Rapid Fire Abstracts, and Moderated Posters, Best Posters and traditional posters. Topics of particular interest to the press will be featured in four press conferences on the cardiovascular (CV) risks of modern life, stroke and arrhythmias, heart failure, and preventing sudden death.

Four Press conferences:

The cardiovascular risks of modern life - Saturday 27 August 12:30-13:30
  • Leisure time physical activity reduces risk of CV death and acute CVD events in older adults

  • Healthy School, Happy School: randomised clinical trial designed to stop obesity in children

  • Low socioeconomic status linked with recurrent CVD events in population with stable CHD

  • Personal activity index for promotion of physical activity and prevention of CVD

Stroke and arrhythmia - life or death- Saturday 27 August 15:00-16:00
  • PRAGUE-16: Direct catheter-based thrombectomy for the treatment of acute ischaemic stroke

  • Detecting atrial fibrillation using existing smartphones without add-ons

  • Aspirin monotherapy for stroke prevention in the real world

  • Stroke and mortality with non-vitamin K antagonist oral anticoagulation versus warfarin in AF

Heart failure - challenges and solutions - Sunday 28 August 13:00-14:00
  • Protective effect of nebivolol on anthracycline-induced cardiotoxicity

  • Increasing readmissions to hospital worsen mortality and decrease survival in heart failure patients

  • AGES-Reykjavik Study: heart failure in the elderly and predictions for the future

  • High morbidity and mortality risk in HF and under treatment with evidence based therapies

Preventing sudden death - diet or device - Sunday 28 August 15:00-16:00
  • Risk of motor vehicle accidents in patients with an implantable cardioverter defibrillator

  • Major disparities in implementation of public access defibrillation programmes

  • MOLI-SANI study: Mediterranean diet associated with lower risk of mortality in patients with CVD

  • Circumstances of sudden death in hypertrophic cardiomyopathy

Register now to secure your place at the largest and most influential cardiovascular congress of the year.

European Society of Cardiology

Related Heart Failure Articles:

New hope for treating heart failure
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Smoking may lead to heart failure by thickening the heart wall
Smokers without obvious signs of heart disease were more likely than nonsmokers and former smokers to have thickened heart walls and reduced heart pumping ability.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
Scientists use 'virtual heart' to model heart failure
A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death.
Increase in biomarker linked with increased risk of heart disease, heart failure, death
In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of six-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Failure Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...